Oncolytic viruses were originally designed as tumour-lysing therapeutics. However, they also initiate systemic antitumour immune responses. Can these viruses be exploited to enhance antitumour immune responses, and how might they be combined with other cancer immunotherapies?
- Brian D. Lichty
- Caroline J. Breitbach
- John C. Bell